Research analysts covering 0O8G.
Recent press releases and 8-K filings for 0O8G.
MDxHealth Announces Q3 2025 Results and ExoDx Acquisition Update
0O8G
Earnings
M&A
Guidance Update
- MDxHealth reported Q3 2025 revenue of $27.4 million, an 18% increase over the prior year, and achieved positive adjusted EBITDA of $1 million.
- Total billable volume for Q3 2025 grew 37% year-over-year to approximately 33,000 tests, driven by a 65% increase in liquid-based tests and an 18% increase in tissue-based tests.
- The company successfully closed the ExoDx acquisition at the end of Q3 2025, expanding its sales organization to 60 direct reps and initiating integration efforts.
- MDxHealth is maintaining its 2025 revenue guidance of $108-$110 million, despite foregoing its germline offering and with no material contribution from ExoDx in Q3.
Nov 12, 2025, 9:30 PM
Quarterly earnings call transcripts for 0O8G.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more